SMR 2022 - 2022 Society for Melanoma Research Congress
Oct 17 - Oct 20, 2022 | EdinburghUK
LARVOL is not affiliated with 2022 Society for Melanoma Research Congress and all trademarks, logos, and brand names are property of their respective owners
Showing 8 abstracts linked to Trials
LATE BREAKING ABSTRACT: Adjuvant therapy with nivolumab versus placebo in patients with stage IIB/C melanoma (CheckMate 76K)
LATE BREAKING ABSTRACT: Adjuvant pembrolizumab (pembro) in stage II melanoma: outcomes in histopathologic subgroups in the phase 3 KEYNOTE-716 study
Results from the randomized controlled phase 3 trial in PD-1 blockade refractory melanoma comparing ipilimumab to TIL therapy
Flash Talks: Tumor Biomarker Analysis From COLUMBUS Part 1: Encorafenib + Binimetinib for BRAF V600E/K-Mutant Advanced or Metastatic Melanoma
Trial design and assay validation for the phase II/III DETECTION trial: Circulating tumor DNA guidEd Therapy for stage IIB/C mElanoma after surgiCal resection
Flash Talks: ZEB1 transcription factor promotes immune escape in melanoma
Phase 2 Trial of Nivolumab/relatlimab in Metastatic Uveal Melanoma
Phase 1 study of fianlimab (FIAN), a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, plus cemiplimab (CEMI) in advanced melanoma (mel)